Improvement of wasting by treatment with a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, MRA in multicentric Castleman's disease. A phase II clinical trial of 28 patients.

被引：0
|
作者：
Nishimoto, N [1 ]
Kanakura, Y [1 ]
Aozasa, K [1 ]
Johkoh, T [1 ]
Nakano, N [1 ]
Nakamura, M [1 ]
Ikeda, Y [1 ]
Sasaki, T [1 ]
Nishioka, K [1 ]
Hara, M [1 ]
Taguchi, H [1 ]
Kimura, Y [1 ]
Kato, Y [1 ]
Kishimoto, T [1 ]
Yoshizaki, K [1 ]
机构：
[1] Osaka Univ, Sch Hlth & Sport Sci, Dept Med Sci 1, Osaka, Japan
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
760
引用
下载
收藏
页码：202A / 203A
页数：2
相关论文
共 43 条
  • [21] Anti-interleukin 6 receptor monoclonal antibody therapy reduced serum interleukin 4 and IgE production in Castleman's disease.
    Nakahara, H
    Hoshino-Yoshio, N
    Kanakura, Y
    Ikeda, Y
    Nakamura, M
    Nakano, S
    Tanaka, T
    Sasaki, T
    Nishioka, K
    Hara, M
    Taguchi, H
    Kimura, Y
    Kato, Y
    Asaoku, H
    Kodama, F
    Aozasa, K
    Johkoh, T
    Kishimoto, T
    Nishimoto, N
    BLOOD, 2005, 106 (11) : 434A - 435A
  • [22] Effective treatment of active Crohn's disease with humanized monoclonal antibody MRA to interleukin-6 receptor: A randomized placebo-controlled trial
    Ito, H
    Takazoe, M
    Fukuda, Y
    Hibi, T
    Kusugami, K
    Andoh, A
    Matsumoto, T
    Yamamura, T
    Azuma, J
    Nishimoto, N
    Yoshizaki, K
    Shimoyama, T
    Kishimoto, T
    GASTROENTEROLOGY, 2003, 124 (04) : A25 - A25
  • [23] Successful Treatment of a Patient with Multicentric Castleman's Disease who Presented with Thrombocytopenia, Ascites, Renal Failure and Myelofibrosis Using Tocilizumab, an Anti-Interleukin-6 Receptor Antibody
    Kawabata, Hiroshi
    Kotani, Shin-ichi
    Matsumura, Yumi
    Kondo, Tadakazu
    Katsurada, Tatsuya
    Haga, Hironori
    Kadowaki, Norimitsu
    Takaori-Kondo, Akifumi
    INTERNAL MEDICINE, 2013, 52 (13) : 1503 - 1507
  • [24] Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease
    Kawabata, Hiroshi
    Tomosugi, Naohisa
    Kanda, Junya
    Tanaka, Yasuhiro
    Yoshizaki, Kazuyuki
    Uchiyama, Takashi
    HAEMATOLOGICA, 2007, 92 (06) : 857 - 858
  • [25] Anti-interleukin 6 receptor antibody tocilizumab reduces the levels of serum hepcidin in patients with Multicentric Castleman's disease
    Kawabata, H.
    Tomosugi, N.
    Kanda, J.
    Tanaka, Y.
    Kadowaki, N.
    Ichinohe, T.
    Ishikawa, T.
    Uchiyama, T.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 529 - 529
  • [26] A multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of Siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with Multicentric Castleman's disease
    Hess, G.
    Kirsch, A.
    Wong, R. S.
    Casper, C.
    Munshi, N.
    Fossa, A.
    Cavet, J.
    Bandekar, R.
    Rothman, M.
    Puchalski, T. A.
    Chaturvedi, S.
    van de Velde, H.
    Vermeulen, J.
    van Rhee, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 77 - 77
  • [27] A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman's Disease
    Wong, Raymond S.
    Casper, Corey
    Munshi, Nikhil
    Ke, Xiaoyan
    Fossa, Alexander
    Simpson, David
    Capra, Marcelo
    Liu, Ting
    Hsieh, Ruey Kuen
    Goh, Yeow Tee
    Zhu, Jun
    Cho, Seok-Goo
    Ren, Hanyun
    Cavet, James
    Bandekar, Rajesh
    Rothman, Margaret
    Puchalski, Thomas A.
    Chaturvedi, Shalini
    de Velde, Helgi van
    Vermeulen, Jessica
    van Rhee, Frits
    BLOOD, 2013, 122 (21)
  • [28] Successful Treatment of a Mesangial Proliferative Glomerulonephritis with Interstitial Nephritis Associated with Castleman's Disease by an Anti-interleukin-6 Receptor Antibody (Tocilizumab)
    Otani, Naoko
    Morishita, Yoshiyuki
    Oh, Iekuni
    Saito, Osamu
    Takemoto, Fumi
    Muto, Shigeaki
    Kusano, Eiji
    INTERNAL MEDICINE, 2012, 51 (11) : 1375 - 1378
  • [29] Dramatic improvement of intractable adult-onset Still's disease by intraveous humanized anti-interleukin 6 receptor antibody (MRA).
    Iwamoto, M
    Nara, H
    Hirata, D
    Okazaki, H
    Kano, S
    Minota, S
    Nishimoto, N
    Yoshizaki, K
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S118 - S118
  • [30] Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial
    Haddad, E
    Paczesny, S
    Leblond, V
    Seigneurin, JM
    Stern, M
    Achkar, A
    Bauwens, M
    Delwail, V
    Debray, D
    Duvoux, C
    Hubert, P
    de Ligny, BH
    Wijdenes, J
    Durandy, A
    Fischer, A
    BLOOD, 2001, 97 (06) : 1590 - 1597
12345